Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.
Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...
Whole-pelvis RT linked to improved PFS for patients with prostate cancer staged TrN0M0, while ADT linked to improved PFS in patients staged N1/M1.
More than 100,000 future cancer cases were projected to result from the 93 million CT examinations performed in 2023, according to a study published April 14 in JAMA Internal Medicine. Low-dose CT ...
FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.
Private companies are capitalizing on this quest for information. Grail’s Galleri blood test screens for more than 50 ...
Source: Getty Images The molecular imaging modality detects metastases earlier and more accurately compared with conventional imaging and has ushered in a new era in metastasis-directed therapy. PSMA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results